Mammas I, Maher F, Theodoridou M, Spandidos D
1st Department of Paediatrics, 'Penteli' Children's Hospital, Athens, Greece.
Department of Infectious Diseases, Liverpool Royal University Hospital, Liverpool, UK.
Hippokratia. 2011 Oct;15(4):299-303.
Vaccination against human papilloma virus (HPV) in childhood is a significant step forward in the reduction of HPV associated morbidity and mortality and a considerable scientific achievement. However, many challenges remain to be overcome if an effective HPV vaccine programme is to be successfully introduced worldwide. The aim of this review is to identify and summarize the new issues concerning HPV vaccination that have emerged since its introduction into clinical practice in school-aged girls. According to the literature, the overall impact of HPV vaccination on cervical cancer is unlikely to be apparent for the next decade. Cost-effectiveness is of particular importance, particularly in developing countries. Determining the age at which the vaccine should be administered, whether to include boys in addition to girls, the costs and the implications for cervical screening are issues that need to be addressed by conducting further research.
儿童期接种人乳头瘤病毒(HPV)疫苗是降低HPV相关发病率和死亡率方面向前迈出的重要一步,也是一项重大的科学成就。然而,若要在全球成功推行有效的HPV疫苗接种计划,仍有许多挑战有待克服。本综述的目的是识别并总结自HPV疫苗在学龄女童中引入临床实践以来出现的有关HPV疫苗接种的新问题。根据文献,HPV疫苗接种对宫颈癌的总体影响在未来十年内不太可能显现。成本效益尤为重要,特别是在发展中国家。确定疫苗接种的年龄、是否除女孩外还应包括男孩、成本以及对宫颈癌筛查的影响等问题,都需要通过进一步研究来解决。